Safety Markers of Adjuvanted Influenza VaccinePhase 4NCT02523287
Placebo Controlled Study to Generate Data Characterising Clinical Events, Physiological Responses and Immune Responses
A Phase 4 study testing Fluad and Saline in people with Safety Markers of Adjuvanted Influenza Vaccine, run by University Hospital, Ghent at 1 site in Belgium.
Trial summary
The purpose of this protocol is to generate a set of data that will be analysed by integrated systems biology approach, for validation in subsequent clinical trials or in animal models. Read more about this study
- Who is it for?
- Ages 18 to 45 yearsHealthy volunteers can take part
- Conditions the study is for
- Safety Markers of Adjuvanted Influenza Vaccine
- What is being tested?
- Fluad and Saline
- Type of treatment
- Vaccines, Injection or infusion
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 240 participants
- Where
- 1 siteBelgium
- Study dates
- 2 Oct 2014to 1 Aug 2016
- Phase
- Phase 4
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 45 years
- All sexes
- Healthy volunteers accepted
- Adult
Who may be able to join
- Healthy male or female subjects aged 18-45 years inclusive.
- Male: Female ratio - Screening will ensure that no more than 2/3 of the population should be of either male or female
- The subject is, in the opinion of the investigator: healthy based on medical history and clinical exam, with no active disease process that could interfere with the study endpoints.
- Has a body Mass Index ≥18 and ≤30
- Is able to read and understand the Informed Consent Form (ICF), and understand study procedures.
- The subject has signed the ICF.
Show all 10Show fewer
- The subject is available for follow-up for the duration of the study.
- The subject agrees to abstain from donating blood during their participation in the study, or longer if necessary.
- If the subject is a heterosexually active female, she is willing to use an effective method of contraception with partner (oral contraceptive pill; intrauterine device; injectable or implanted contraceptive; condoms incorporating spermicide if using these; physiological or anatomical sterility) from 30 days prior to, and 3 months after, vaccination. Willing to undergo urine pregnancy tests prior to vaccination at screening.
- The subject has venous access sufficient to allow blood sampling as per the protocol.
Who cannot join
- Pregnant or lactating at any point during the study from screening to final follow up.
- Hypersensitivity to the active components of FLUAD, any of the excipients, eggs, chicken proteins, kanamycin and neomycin sulphate, formaldehyde, and cetyltrimetholammonium bromide or those who have had a previous life-threatening reaction to previous influenza vaccinations.
- Presence of primary or acquired immunodeficiency states with a total lymphocyte count less than 1,200 per mm3 or presenting other evidence of lack of cellular immune competence e.g. leukaemias, lymphomas, blood dyscrasias, or patients receiving immunosuppressive therapy (including regular use of oral or parenteral corticosteroids).
- Use of any immune suppressing or immunomodulating drugs within 6 months of Visit 1.
- Regular use of non-steroidal anti-inflammatory drugs (oral or parenteral route) within 6 months of Visit 1 considered by the study physician as likely to interfere with immune responses.
- Current intake of excessive amounts of alcohol and/or caffeine (as evaluated by the investigator) and not willing to adapt this use during the study period.
Show all 15Show fewer
- Currently performing extreme physical activities (as evaluated by the investigator) and not willing to adapt this use during the study period.
- Receipt of a vaccine within 30 days of visit 1, or requirement to receive another vaccine within the study period.
- Vaccination with the 2014/2015 seasonal influenza vaccine and/or any other seasonal influenza vaccine within the last 6 months before the first study visit.
- Presence of an acute severe febrile illness at time of immunisation.
- History of alcohol, narcotic, benzodiazepine, rilatine, or other substance abuse or dependence within the 12 months preceding Visit 1.
- Currently participating in another clinical study with an investigational or non-investigational drug or device, or has participated in a clinical trial within the 3 months preceding Visit 1.
- Any condition that, in the investigator's opinion, compromises the subject's ability to meet protocol requirements or to complete the study.
- Receipt of blood products or immunoglobin, or blood donation, within 3 months of screening.
- Unable to read and speak Dutch or English to a fluency level adequate for the full comprehension of procedures required in participation and consent.
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Clinical Study to Generate a Set of Data Characterising Clinical Events, Physiological Responses, and Innate and Adaptive Immune Responses Following a Single IM Immunisation With Fluad Seasonal Influenza Vaccine or Placebo in Healthy Adults
The purpose of this protocol is to generate a set of data that will be analysed by integrated systems biology approach, for validation in subsequent clinical trials or in animal models.
240 healthy participants (18-45y) will be enrolled, 228 will be administered a dose of Fluad on Day 0, 12 will receive a placebo on Day 0.
Read the detailed description
This study is part of the BIOVACSAFE project, a 5-year project funded by the Innovative Medicine Initiative, which will undertake a series of correlated clinical studies that will apply and develop technologies to generate clinical data on inflammation with licensed vaccines as benchmarks, and identify biomarkers to predict acceptable reactogenicity, for correlation with standardized clinical readouts and inflammatory markers assessed in natural infections.
The purpose of this protocol is to generate a set of data that will be analysed by integrated systems biology approach, for validation in subsequent clinical trials or in animal models. The dataset will broadly characterise:
- Physiological responses at various time points after immunisation by measuring:
- Local and systemic vaccine-related clinical events.
- Physiological assessments: heart rate, temperature, blood pressure.
- Haematology (blood counts and ESR), biochemistry parameters.
- Metabolic, innate and adaptive immune responses including:
- Innate immune activation detected by global gene expression in whole blood
- Metabolic responses detected by metabolic gene expression and pathway activation in whole blood
- Adaptive immunity determined by:
- Humoral immune response via serum anti-influenza HAI titre ii. Cellular immune response via enumeration of HA-specific CD4+ T cells expressing activation markers and/or cytokines following in vitro stimulation and analysis by flow cytometry.
- Innate and adaptive immune activation detected by gene pathway activation in whole blood
- Immune activation detected by concentration of selected inflammatory soluble mediators in serum including:
- chemokines and cytokines ii. acute phase proteins
- Genetic testing of subjects when deemed necessary (genetic testing analysis may be SNIP analysis or full genome analysis).
- Correlations in changes in innate and adaptive immune activation and metabolism with adverse events, haematology and biochemistry panels, genotype and physiological assessments
The investigators will biobank all samples for the duration of the BIOVACSAFE programme so that the investigators can selectively analyse different samples and different time points depending on the results generated, principally from the gene expression analysis of whole blood.
- Being tested
- Fluad, Saline
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
FluadBiological
Randomized assignment
SalineBiological
Randomized assignment
| Study group | Role | What they receive |
|---|---|---|
| Fluad - 5 study visits (114 subjects) | Active comparator | 0,5 ml adjuvanted, subunit seasonal trivalent influenza vaccine (2014-2015). Administration: Intramuscular, deltoid.
5 out-patient visits: Day 0 (blood sampling, vaccination), Day 1 (blood sampling), Day 3 (blood sampling), Day 7 (blood sampling), Day 21 (blood sampling). Receives: Biological: Fluad |
| Fluad - 3 study visits (114 subjects) | Active comparator | 0,5 ml adjuvanted, subunit seasonal trivalent influenza vaccine (2014-2015). Administration: Intramuscular, deltoid.
3 out-patient visits: Day 0 (blood sampling, vaccination), Day 1 (blood sampling), Day 7 (blood sampling). On day 21 there's a phone call for safety follow-up. Receives: Biological: Fluad |
| Saline - 5 study visits (6 subjects) | Placebo comparator | 0,5 ml saline. Administration: Intramuscular, deltoid.
5 out-patient visits: Day 0 (blood sampling, vaccination), Day 1 (blood sampling), Day 3 (blood sampling), Day 7 (blood sampling), Day 21 (blood sampling). Receives: Biological: Saline |
| Saline - 3 study visits (6 subjects) | Placebo comparator | 0,5 ml saline. Administration: Intramuscular, deltoid.
3 out-patient visits: Day 0 (blood sampling, vaccination), Day 1 (blood sampling), Day 7 (blood sampling). On day 21 there's a phone call for safety follow-up. Receives: Biological: Saline |
What is being measured
The primary outcome is the main question the study is designed to answer.
Frequency of local and systemic vaccine-related clinical events.
Measured: At all time points from vaccination up to 28 days after vaccination
Change from pre-immunisation baseline values in pulse.
Measured: At all time points from time of vaccination up to 28 days after vaccination
Change from pre-immunisation baseline values in haematology (blood counts and ESR) parameters.
Measured: At selected time points from time of vaccination up to 28 days after vaccination
Change from pre-immunisation baseline values in global gene expression measured on whole blood samples.
Measured: At selected time points from time of vaccination up to 28 days after vaccination
Change from pre-immunisation baseline values in metabolic gene expression and pathway activation measured on whole blood samples.
Measured: At selected time points from time of vaccination up to 28 days after vaccination
Change from pre-immunisation baseline values in serum HAI titre in serum samples.
Measured: At selected time points from time of vaccination up to 28 days after vaccination
Change from pre-immunisation values of adaptive cellular immune response via enumeration of HA-specific CD4+ T cells expressing activation markers and/or cytokines following in vitro stimulation and analysis by flow cytometry
Measured: At 7 days after vaccination
Change from pre-immunisation baseline values in concentration of selected cytokines and acute phase proteins in serum samples
Measured: At selected time points from time of vaccination up to 28 days after vaccination
Change from pre-immunisation baseline values in PBMC cytokine secretion, proliferation or surface markers in response to in vitro antigen stimulation.
Measured: At selected time points from time of vaccination up to 28 days after vaccination
Genetic testing of subject (only when deemed necessary: may be SNIP analysis or full genome analysis)
Measured: Up to 2 years after vaccination
Change from pre-immunisation baseline values in body temperature.
Measured: At all time points from time of vaccination up to 28 days after vaccination
Change from pre-immunisation baseline values in blood pressure.
Measured: At all time points from time of vaccination up to 28 days after vaccination
Change from pre-immunisation baseline values in creatinin
Measured: At selected time points from time of vaccination up to 28 days after vaccination
Change from pre-immunisation baseline values in CRP
Measured: At selected time points from time of vaccination up to 28 days after vaccination
Change from pre-immunisation baseline values in AST/ALT
Measured: At selected time points from time of vaccination up to 28 days after vaccination
Change from pre-immunisation baseline values in albumin
Measured: At selected time points from time of vaccination up to 28 days after vaccination
Change from pre-immunisation baseline values in eGFR
Measured: At selected time points from time of vaccination up to 28 days after vaccination
Change from pre-immunisation baseline values in GGT
Measured: At selected time points from time of vaccination up to 28 days after vaccination
Change from pre-immunisation baseline values in total protein
Measured: At selected time points from time of vaccination up to 28 days after vaccination
Change from pre-immunisation baseline values in total prothrombin/fibrinogen
Measured: At selected time points from time of vaccination up to 28 days after vaccination
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted14 Aug 2015 (estimated)
- Study start2 Oct 2014
- Primary completion1 Aug 2016
- Study completion1 Aug 2016
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Safety Markers of Adjuvanted Influenza VaccineStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 4
- Primary purpose
- Basic science
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind
- Who is masked
- Participant, Care provider, Investigator
- Enrolment
- 240 participants (actual)
Sponsor and investigators
- Lead sponsor
- University Hospital, Ghent
- Sponsor type
- University, hospital or other
- Collaborators
- University of Surrey, Novartis Vaccines, Max Planck Institute for Infection Biology, deCODE genetics, VisMederi srl, GlaxoSmithKline, Innovative Medicines Initiative
- Responsible party
- Sponsor
- Investigators
- Geert Leroux-Roels, Prof,MD, Principal investigator, Center for Vaccinology
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02523287
- Sponsor's protocol ID
- BioVacSafe - Fluad
- Status last verified
- Dec 2022
- First submitted
- 24 Jun 2015
- Last updated
- 20 Dec 2022
- Results posted
- No
- Data monitoring committee
- No
Publications
Muturi-Kioi V, Lewis D, Launay O, Leroux-Roels G, Anemona A, Loulergue P, Bodinham CL, Aerssens A, Groth N, Saul A, Podda A. Neutropenia as an Adverse Event following Vaccination: Results from Randomized Clinical Trials in Healthy Adults and Systematic Review. PLoS One. 2016 Aug 4;11(8):e0157385. doi: 10.1371/journal.pone.0157385. eCollection 2016.
PubMed 27490698
Study at a glance
From the registry record, last updated by the sponsor on 20 Dec 2022. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Clinical Study to Generate a Set of Data Characterising Clinical Events, Physiological Responses, and Innate and Adaptive Immune Responses Following a Single IM Immunisation With Fluad Seasonal Influenza Vaccine or Placebo in Healthy Adults
- ClinicalTrials.gov ID
- NCT02523287
- Acronym / sponsor ID
- BioVacSafe - Fluad
- Phase
- Phase 4
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 240 participants (actual)
- Lead sponsor
- University Hospital, GhentUniversity, hospital or other
- Collaborators
- University of Surrey, Novartis Vaccines, Max Planck Institute for Infection Biology, deCODE genetics, VisMederi srl, GlaxoSmithKline, Innovative Medicines Initiative
- Study start
- 2 Oct 2014 (actual)
- Primary completion
- 1 Aug 2016 (actual)
- Study completion
- 1 Aug 2016 (actual)
- First posted
- 14 Aug 2015 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this protocol is to generate a set of data that will be analysed by integrated systems biology approach, for validation in subsequent clinical trials or in animal models.
240 healthy participants (18-45y) will be enrolled, 228 will be administered a dose of Fluad on Day 0, 12 will receive a placebo on Day 0.
Detailed description
This study is part of the BIOVACSAFE project, a 5-year project funded by the Innovative Medicine Initiative, which will undertake a series of correlated clinical studies that will apply and develop technologies to generate clinical data on inflammation with licensed vaccines as benchmarks, and identify biomarkers to predict acceptable reactogenicity, for correlation with standardized clinical readouts and inflammatory markers assessed in natural infections.
The purpose of this protocol is to generate a set of data that will be analysed by integrated systems biology approach, for validation in subsequent clinical trials or in animal models. The dataset will broadly characterise:
- Physiological responses at various time points after immunisation by measuring:
- Local and systemic vaccine-related clinical events.
- Physiological assessments: heart rate, temperature, blood pressure.
- Haematology (blood counts and ESR), biochemistry parameters.
- Metabolic, innate and adaptive immune responses including:
- Innate immune activation detected by global gene expression in whole blood
- Metabolic responses detected by metabolic gene expression and pathway activation in whole blood
- Adaptive immunity determined by:
- Humoral immune response via serum anti-influenza HAI titre ii. Cellular immune response via enumeration of HA-specific CD4+ T cells expressing activation markers and/or cytokines following in vitro stimulation and analysis by flow cytometry.
- Innate and adaptive immune activation detected by gene pathway activation in whole blood
- Immune activation detected by concentration of selected inflammatory soluble mediators in serum including:
- chemokines and cytokines ii. acute phase proteins
- Genetic testing of subjects when deemed necessary (genetic testing analysis may be SNIP analysis or full genome analysis).
- Correlations in changes in innate and adaptive immune activation and metabolism with adverse events, haematology and biochemistry panels, genotype and physiological assessments
The investigators will biobank all samples for the duration of the BIOVACSAFE programme so that the investigators can selectively analyse different samples and different time points depending on the results generated, principally from the gene expression analysis of whole blood.
Study design
- Primary purpose
- Basic science
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind (participant, care provider, investigator)
- Number of arms
- 4
| Arm | Type | Receives |
|---|---|---|
| Fluad - 5 study visits (114 subjects) | Active comparator | Biological: Fluad0,5 ml adjuvanted, subunit seasonal trivalent influenza vaccine (2014-2015). Administration: Intramuscular, deltoid. 5 out-patient visits: Day 0 (blood sampling, vaccination), Day 1 (blood sampling), Day 3 (blood sampling), Day 7 (blood sampling), Day 21 (blood sampling). |
| Fluad - 3 study visits (114 subjects) | Active comparator | Biological: Fluad0,5 ml adjuvanted, subunit seasonal trivalent influenza vaccine (2014-2015). Administration: Intramuscular, deltoid. 3 out-patient visits: Day 0 (blood sampling, vaccination), Day 1 (blood sampling), Day 7 (blood sampling). On day 21 there's a phone call for safety follow-up. |
| Saline - 5 study visits (6 subjects) | Placebo comparator | Biological: Saline0,5 ml saline. Administration: Intramuscular, deltoid. 5 out-patient visits: Day 0 (blood sampling, vaccination), Day 1 (blood sampling), Day 3 (blood sampling), Day 7 (blood sampling), Day 21 (blood sampling). |
| Saline - 3 study visits (6 subjects) | Placebo comparator | Biological: Saline0,5 ml saline. Administration: Intramuscular, deltoid. 3 out-patient visits: Day 0 (blood sampling, vaccination), Day 1 (blood sampling), Day 7 (blood sampling). On day 21 there's a phone call for safety follow-up. |
Who may qualify
- Ages
- 18 to 45 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (10 listed)
- Healthy male or female subjects aged 18-45 years inclusive.
- Male: Female ratio - Screening will ensure that no more than 2/3 of the population should be of either male or female
- The subject is, in the opinion of the investigator: healthy based on medical history and clinical exam, with no active disease process that could interfere with the study endpoints.
- Has a body Mass Index ≥18 and ≤30
- Is able to read and understand the Informed Consent Form (ICF), and understand study procedures.
Key exclusion criteria (15 listed)
- Pregnant or lactating at any point during the study from screening to final follow up.
- Hypersensitivity to the active components of FLUAD, any of the excipients, eggs, chicken proteins, kanamycin and neomycin sulphate, formaldehyde, and cetyltrimetholammonium bromide or those who have had a previous life-threatening reaction to previous influenza vaccinations.
- Presence of primary or acquired immunodeficiency states with a total lymphocyte count less than 1,200 per mm3 or presenting other evidence of lack of cellular immune competence e.g. leukaemias, lymphomas, blood dyscrasias, or patients receiving immunosuppressive therapy (including regular use of oral or parenteral corticosteroids).
- Use of any immune suppressing or immunomodulating drugs within 6 months of Visit 1.
- Regular use of non-steroidal anti-inflammatory drugs (oral or parenteral route) within 6 months of Visit 1 considered by the study physician as likely to interfere with immune responses.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| FluadRandomized assignment | Biological | Fluad - 3 study visits (114 subjects), Fluad - 5 study visits (114 subjects) |
| SalineRandomized assignment | Biological | Saline - 3 study visits (6 subjects), Saline - 5 study visits (6 subjects) |
Primary outcome
Frequency of local and systemic vaccine-related clinical events.
Time frame: At all time points from vaccination up to 28 days after vaccination
Change from pre-immunisation baseline values in pulse.
Time frame: At all time points from time of vaccination up to 28 days after vaccination
Change from pre-immunisation baseline values in haematology (blood counts and ESR) parameters.
Time frame: At selected time points from time of vaccination up to 28 days after vaccination
Change from pre-immunisation baseline values in global gene expression measured on whole blood samples.
Time frame: At selected time points from time of vaccination up to 28 days after vaccination
Change from pre-immunisation baseline values in metabolic gene expression and pathway activation measured on whole blood samples.
Time frame: At selected time points from time of vaccination up to 28 days after vaccination
Change from pre-immunisation baseline values in serum HAI titre in serum samples.
Time frame: At selected time points from time of vaccination up to 28 days after vaccination
Change from pre-immunisation values of adaptive cellular immune response via enumeration of HA-specific CD4+ T cells expressing activation markers and/or cytokines following in vitro stimulation and analysis by flow cytometry
Time frame: At 7 days after vaccination
Change from pre-immunisation baseline values in concentration of selected cytokines and acute phase proteins in serum samples
Time frame: At selected time points from time of vaccination up to 28 days after vaccination
Change from pre-immunisation baseline values in PBMC cytokine secretion, proliferation or surface markers in response to in vitro antigen stimulation.
Time frame: At selected time points from time of vaccination up to 28 days after vaccination
Genetic testing of subject (only when deemed necessary: may be SNIP analysis or full genome analysis)
Time frame: Up to 2 years after vaccination
Change from pre-immunisation baseline values in body temperature.
Time frame: At all time points from time of vaccination up to 28 days after vaccination
Change from pre-immunisation baseline values in blood pressure.
Time frame: At all time points from time of vaccination up to 28 days after vaccination
Change from pre-immunisation baseline values in creatinin
Time frame: At selected time points from time of vaccination up to 28 days after vaccination
Change from pre-immunisation baseline values in CRP
Time frame: At selected time points from time of vaccination up to 28 days after vaccination
Change from pre-immunisation baseline values in AST/ALT
Time frame: At selected time points from time of vaccination up to 28 days after vaccination
Change from pre-immunisation baseline values in albumin
Time frame: At selected time points from time of vaccination up to 28 days after vaccination
Change from pre-immunisation baseline values in eGFR
Time frame: At selected time points from time of vaccination up to 28 days after vaccination
Change from pre-immunisation baseline values in GGT
Time frame: At selected time points from time of vaccination up to 28 days after vaccination
Change from pre-immunisation baseline values in total protein
Time frame: At selected time points from time of vaccination up to 28 days after vaccination
Change from pre-immunisation baseline values in total prothrombin/fibrinogen
Time frame: At selected time points from time of vaccination up to 28 days after vaccination
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 20 Dec 2022.
- Derived from this study: PubMed 27490698Muturi-Kioi V, Lewis D, Launay O, Leroux-Roels G, Anemona A, Loulergue P, Bodinham CL, Aerssens A, Groth N, Saul A, Podda A. Neutropenia as an Adverse Event following Vaccination: Results from Randomized Clinical Trials in Healthy Adults and Systematic Review. PLoS One. 2016 Aug 4;11(8):e0157385. doi: 10.1371/journal.pone.0157385. eCollection 2016.
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Geert Leroux-Roels, Prof,MD principal investigator
Center for Vaccinology
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 4 study testing Fluad and Saline in people with Safety Markers of Adjuvanted Influenza Vaccine, run by University Hospital, Ghent at 1 site in Belgium.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 10 inclusion and 15 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 20 Dec 2022. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Belgium. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 4 studies take place after a treatment is approved, to learn more about its long-term benefits and risks in everyday use.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Frequency of local and systemic vaccine-related clinical events. (time frame: At all time points from vaccination up to 28 days after vaccination). The study lists 20 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT02523287, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 20 Dec 2022; AzTrials last refreshed its copy on 30 Oct 2026.